IP Library Granted Patent US 8,114,875
Granted Patent B2
US 8,114,875 · App. 11/793,633 · Granted Feb 14, 2012

Substituted N-heterocyclic compounds and their use as dopamine D

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,875
App. No.
11/793,633
Granted
Feb 14, 2012
Kind
B2
Abstract

The invention relates to substituted N-heterocyclic compounds of general formula (I.A) and to the tautomers of the compounds the physiologically acceptable salts of the compounds and the physiologically acceptable salts of the tautomers of the compounds. The invention also relates to the use of these compounds and their pharmacologically acceptable salts in the production of a pharmaceutical agent for treating diseases that respond to the influence exerted by dopamine D 3 receptor ligands, especially for treating diseases of the central nervous system, especially schizophrenia and/or depression.

Claims (17)

1. A substituted N-heterocyclic compound of the formula (I.A)

in which

W is N;

R 1 is OH, methyl, isopropyl, tertbutyl, CF 3 , cyclobutyl, cyclohexyl, phenyl, p-fluorophenyl, m-fluorophenyl, o-fluorophenyl, p-methylphenyl, m-methylphenyl, o-methylphenyl or 2-furyl;

R 2 is H, C 1 -C 4 -alkyl, CF 3 , halogen or cyano;

N is 4;

A 2 is a 1- to 2-membered hydrocarbon chain which may have 1 or 2 methyl groups as substituents, in which 1 carbon atom may be replaced by a carbonyl group;

Q is phenyl which optionally has 1, 2, or 3 substituents R Q which are selected independently of one another from methyl, ethyl, n-propyl, isopropyl, tert-butyl, cyclopropyl, cyclobutyl, hydroxyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, fluorine, chlorine, cyano, and dimethylamino;

and the tautomers of the compound I.A., the physiologically acceptable salts of the compound I.A and the physiologically acceptable salts of the tautomers of the compound I.A.

2. The compound as claimed in claim 1 , in which A 2 is CH 2 , CH 2 CH 2 , CO, CH 2 CO, or COCH 2 .

3. The compound as claimed in claim 2 , in which A 2 is CH 2 .

4. The compound as claimed in claim 1 , in which Q is phenyl which has two substituents R Q .

5. The compound as claimed in claim 4 , in which the two substituents R Q are located in position 2,3 on the phenyl ring.

6. The compound as claimed in claim 4 , in which the two substituents R Q are located in position 2,4 on the phenyl ring.

7. The compound as claimed in claim 4 , in which the two substituents R Q are located in position 3,4 on the phenyl ring.

8. A pharmaceutical composition comprising the compound of claim 1 and/or salt thereof, together with physiologically acceptable carriers and/or excipients.

9. A method for treating schizophrenia, or parkinsonism, the method comprising administering the compound of claim 1 or a pharmacologically acceptable salt thereof or a tautomer of the at least one compound as defined in claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2013
From: ABBOTT GMBH & CO KG
To: ABBVIE DEUTSCHLAND GMBH & CO KG
Reel/Frame 030804/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2008
From: GENESTE, HERVE; SAUER, DARYL R.
To: ABBOTT GMBH & CO. KG
Reel/Frame 021445/0624 →